SARS-CoV-2 spike mutations alter structure and energetics to modulate ACE2 binding immune evasion and viral adaptation.

bamlanivimab (LY-CoV555) - Eli Lilly, AbCellera, National Institute of Allergy and Infectious Diseases

http://www.ncbi.nlm.nih.gov/pubmed/41152301

Abir Alamro; Amani Alghamdi; Dalia Fouad; Farid Ataya

Oct 29, 2025